GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors (GD2CART-BEV)
A Phase Ib Safety, Dose Finding and Feasibility Trial of GD2IL18CART Combined With Bevacizumab in Patients With Relapsed or Refractory GD2 Positive Solid Cancers
This study will test a chimeric antigen receptor (CAR) T-cell treatment combined with bevacizumab in children and young adults with relapsed or refractory neuroblastoma, Ewing sarcoma, or osteosarcoma.
The CAR T-cell treatment, called GD2IL18CART, is made from a patient's own T cells. The T cells are genetically modified to recognize GD2, a molecule found on the surface of these cancers, and to release the immune-stimulating protein interleukin-18 (IL-18) when they encounter tumor cells. Bevacizumab is an antibody that blocks vascular endothelial growth factor (VEGF), a protein that affects tumor blood vessels and may make it difficult for immune cells to enter tumors. Combining bevacizumab with GD2IL18CART may therefore help more CAR T cells reach the tumor and improve their antitumor activity.
The main goals of this study are to determine whether the combination can be given safely, identify a recommended dose of GD2IL18CART for use with bevacizumab, and look for early evidence of antitumor activity. The study will also examine blood and tumor samples to better understand how the treatment affects CAR T cells and the tumor environment.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Gedetailleerde beschrijving
This is an international, prospective, multicenter, open-label, non-randomized phase Ib dose-escalation and dose-expansion study evaluating GD2IL18CART in combination with bevacizumab in children, adolescents, and young adults with relapsed or refractory GD2-positive neuroblastoma, Ewing sarcoma, or osteosarcoma.
GD2IL18CART is an autologous chimeric antigen receptor (CAR) T-cell product directed against the tumor-associated antigen GD2 and engineered for antigen-inducible secretion of interleukin-18 (IL-18). Clinical investigation of GD2IL18CART as a single agent demonstrated robust CAR T-cell expansion and established doses that could be administered with a manageable safety profile. However, clinical activity remained limited, particularly at non-osseous tumor sites and in Ewing sarcoma and osteosarcoma.
The combination with bevacizumab is intended to address tumor microenvironmental barriers that may limit CAR T-cell access and activity. Bevacizumab is a monoclonal antibody that neutralizes vascular endothelial growth factor A (VEGF-A). Persistent VEGF signaling contributes to abnormal tumor vasculature that can restrict immune-cell trafficking and promote local immunosuppression. In preclinical models of Ewing sarcoma and neuroblastoma, vascular endothelial growth factor/vascular endothelial growth factor receptor (VEGF/VEGFR) pathway inhibition increased intratumoral accumulation and antitumor activity of GD2-directed CAR T cells. Bevacizumab also enhanced the antitumor activity of the clinical GD2IL18CART product. These findings provide the rationale for evaluating the combination clinically.
Following leukapheresis and manufacture of the autologous GD2IL18CART product, participants will receive lymphodepleting chemotherapy with fludarabine and cyclophosphamide on days -6 to -4. Bevacizumab will be administered intravenously at 15 mg/kg on day -3, followed by a single intravenous infusion of GD2IL18CART on day 0. Additional bevacizumab doses will be administered every 3 weeks for up to five doses in total, unless treatment is discontinued earlier according to protocol-defined criteria. The timing of bevacizumab is intended to initiate VEGF inhibition before CAR T-cell infusion and maintain VEGF inhibition during the early period of CAR T-cell trafficking, expansion, and persistence.
GD2IL18CART dose escalation will follow a cohort-based single ascending dose design. The starting dose is lower than the doses established during previous clinical investigation of GD2IL18CART as a single agent because bevacizumab may increase tumor infiltration and biological activity of the CAR T cells. Cohorts of three participants will be treated sequentially, with predefined stopping rules and independent Data Monitoring Committee review guiding dose escalation. The objective of the dose-escalation phase is to characterize the safety of the combination and determine a recommended GD2IL18CART dose for use with bevacizumab.
After determination of the recommended combination dose, disease-specific expansion cohorts will enroll participants with neuroblastoma, Ewing sarcoma, and osteosarcoma, with up to six participants per disease entity treated at the recommended dose. The expansion phase will further characterize safety, feasibility, biological activity, and preliminary antitumor activity of the combination.
Tumor response will be assessed at weeks 6 and 12 and at months 6 and 12. Participants will be followed within this study through month 12. Long-term follow-up after genetically modified cell therapy will continue for up to 15 years in a separate long-term follow-up study.
An integrated translational research program will investigate the biological effects of the combination. Longitudinal analysis of blood samples will assess CAR T-cell expansion, persistence, phenotype, and immune responses. Mandatory on-treatment tumor biopsies obtained on day 14 will be analyzed using molecular and spatial approaches to investigate CAR T-cell trafficking and function within the tumor microenvironment and to identify potential biological determinants of response and resistance.
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Fase 1
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Claudia Rossig, MD
- Telefoonnummer: 00492518347742
- E-mail: rossig@ukmuenster.de
Studie Contact Back-up
- Naam: Andreas Mackensen, MD
- Telefoonnummer: 004991318535954
- E-mail: andreas.mackensen@uk-erlangen.de
Studie Locaties
-
-
North Rhine-Westphalia
-
Münster, North Rhine-Westphalia, Duitsland, 48149
- Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Participants must have relapsed and/or refractory neuroblastoma, osteosarcoma, or Ewing sarcoma judged to be incurable with conventional treatment and meet the following disease-specific requirements:
- Neuroblastoma: Patients with locoregional recurrence must have received surgery and/or radiotherapy followed by relapse chemotherapy. Patients with metastatic recurrence after initial classification as intermediate risk must have received high-risk therapy. Patients with recurrence after initial classification as high risk must have received relapse chemotherapy alone or combined with immunotherapy.
- Osteosarcoma: Patients must have received frontline therapy and at least one prior line of relapse systemic anticancer therapy for relapsed or refractory disease. Patients with an isolated relapse manifestation (lung metastasis or local relapse) must have unresectable disease.
- Ewing sarcoma: Patients must have received frontline therapy and at least one prior line of relapse chemotherapy according to standard regimens. Patients with an isolated lung relapse must have received pulmonary irradiation during frontline or relapse therapy.
-
All participants must additionally meet the following criteria:
- GD2 expression on tumor cells in an archival biopsy assessed by the central reference laboratory. GD2-positive tumor is defined as GD2 at least 50% of tumor cells expressing GD2 at an intensity of 2+ or higher, using an immunofluorescence assay for specific detection of GD2 expression in formalin-fixed, paraffin-embedded or frozen tumor tissue with semiquantitative evaluation.
- Evaluable disease based on Response Evaluation Criteria in Solid Tumors for all disease entities or, in cases of diffuse bone/bone marrow metastases, by whole-body nuclear medicine imaging (e.g. metaiodobenzylguanidine (MIBG)) scan for neuroblastoma or positron emission tomography (PET) based imaging.
- Age ≥1 year and ≤25 years.
- Absolute cluster of differentiation 3 (CD3)-positive T-cell count ≥200/µL.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2 for participants >16 years of age or Lansky performance score ≥60 for participants ≤16 years of age at screening.
- No childbearing potential, or negative pregnancy test at screening and before chemotherapy in participants with childbearing potential.
- Signed and dated informed consent/assent by participants and/or their caregivers before any trial-specific procedure.
Exclusion Criteria:
-
Active solid central nervous system (CNS) metastases or metabolically active metastatic disease in the skull with direct contact to the dura.
-
Current autoimmune disease or history of autoimmune disease with potential CNS involvement.
-
Active clinically significant CNS dysfunction, including but not limited to uncontrolled seizure disorders, cerebrovascular ischemia or hemorrhage, dementia, or paralysis.
-
History of an additional malignancy other than non-melanoma skin cancer or carcinoma in situ unless disease-free for ≥3 years.
-
Pre-existing severe lung disease, oxygen requirement of >28% inspired oxygen (O2) supplementation, or active pulmonary infiltrates on X-ray.
-
Cardiac function: Pediatric patients (˂18 yrs): fractional shortening <28% or left ventricular ejection fraction <50% by echocardiography, young adult patients (18-25 yrs): left ventricular ejection fraction <50% by echocardiography.
-
Renal function: GFR ≤29 mL/min/1.73 m22 by CKD-EPI for patients ≥18 yrs or creatinine clearance ≤29 mL/min/1.73 m2 by Schwartz formula for patients <18 yrs of age.
-
Liver function: serum bilirubin >3 times the upper limit of normal (ULN) or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >5 times ULN, unless attributable to liver infiltration by the underlying malignant disease.
-
Hematological function: absolute neutrophil count (ANC) <500/µL or platelet count <50 × 10³/µL.
-
Presence of any active infection.
-
Bevacizumab-specific exclusion criteria:
- uncontrolled arterial hypertension, history of hypertensive crisis or hypertensive encephalopathy,
- clinically significant proteinuria.
- history of gastrointestinal perforation or clinically significant fistula, or current condition considered to confer a clinically relevant increased risk of gastrointestinal perforation,
- clinically significant bleeding or coagulopathy, including recent clinically significant hemoptysis or pulmonary hemorrhage,
- any history of clinically significant arterial thromboembolic event, including myocardial infarction, cerebrovascular accident, transient ischemic attack, or arterial thrombosis/embolism,
- clinically significant venous thromboembolism within 6 months before the first dose of bevacizumab,
- history of posterior reversible encephalopathy syndrome (PRES),
- clinically significant cardiovascular disease beyond inadequate left ventricular ejection fraction, e.g., uncontrolled arrhythmia, congestive heart failure, unstable angina.
-
Rapidly progressive disease that in the estimation of the Investigator would compromise ability to complete study therapy.
-
Pregnant or breast-feeding females.
-
Concurrent or recent prior therapies:
- High-dose chemotherapy with autologous stem cell transplantation or requiring autologous stem cell rescue or anticancer biologicals (e.g. mifamurtide) or radiation therapy or major surgery within 30 days prior to leukapheresis.
- CAR T cells within 3 months before leukapheresis.
- Checkpoint inhibitors within less than 2 half lives prior to apheresis.
- Neuroblastoma patients who have relapsed after allogeneic or haploidentical stem cell transplantation must be at least 100 days posttransplant, with no evidence of GVHD and not taking immunosuppressive agents for at least 30 days prior to leukapheresis.
- I-131 MIBG therapy (neuroblastoma) or other targeted radionuclide therapy must be completed at least 3 months prior to apheresis.
- GD2-specific antibody therapy with dinutuximab beta or naxitamab within 40 days (5 half-lives) before apheresis.
- Antiproliferative chemotherapy, epigenetic agents, antibody-drug conjugates, or antibodies targeting antigens other than GD2 within 3 weeks prior apheresis.
- Immunosuppressive agents other than steroids within 2 weeks before apheresis.
- Short-acting molecularly targeted agents (kinase inhibitors) within 7 days before apheresis.
- Systemic corticosteroids, except physiologic replacement dosing, within 7 days before apheresis.
- Live vaccines within 30 days before apheresis.
-
Hypersensitivity against any drug or its ingredients/impurities that is scheduled or likely to be given during trial participation, e.g. as part of the mandatory preparative chemotherapy, pre-medication for infusion, rescue medication/salvage therapies for treatment related toxicities.
-
Contraindication to trial related procedures as judged by the Investigator, e.g., tumor biopsy.
-
Female patients of child-bearing potential not willing to practice a highly effective form of birth control from the time of signing the informed consent form and for 12 months after dosing the IMP.
-
Male patients of fathering potential not willing to practice a highly effective form of birth control from the time of signing the informed consent form and for 12 months after dosing the IMP.
-
Concurrent participation in another interventional trial that could interact with this trial, e.g. CAR T trials.
-
Cerebral dysfunction, legal incapacity of adult patients; Committal to an institution on judicial or official order.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Sequentiële toewijzing
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: GD2IL18CART + bevacizumab
Participants receive a single intravenous infusion of freshly prepared autologous GD2IL18CART cells in combination with intravenous bevacizumab administered every 3 weeks for up to 5 doses. |
Combination of GD2IL1CART (IMP1, EU CT 2022-501725-21-00) with a monoclonal antibody against vascular endothelial growth factor, bevacizumab (IMP2) to promote effective CAR T-cell accumulation and function within the immunosuppressive tumor microenvironment (TME).
Andere namen:
In combination with GD2IL18CART (IMP1, EU CT 2022-501725-21-00) |
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence and severity of adverse events
Tijdsspanne: Through 12 months after GD2IL18CART infusion
|
Incidence and severity of adverse events (AEs), graded according to CTCAE version 6.0 |
Through 12 months after GD2IL18CART infusion
|
|
Dose-limiting toxicities and recommended dose - dose-finding part
Tijdsspanne: 28 days after IMP infusion
|
Incidence of protocol-defined dose-limiting toxicities (DLTs) and determination of the recommended dose (RD) of GD2IL18CART in combination with bevacizumab using a rule-based small-cohort design |
28 days after IMP infusion
|
|
Recommended dose of GD2IL18CART in combination with bevacizumab
Tijdsspanne: Through completion of the protocol-defined DLT assessment period of 28 days for the final dose-finding cohort
|
Determination of the recommended dose (RD) of GD2IL18CART in combination with bevacizumab using a rule-based small-cohort dose-escalation design, based on observed dose-limiting toxicities (DLTs) and protocol-defined dose-escalation and stopping rules. |
Through completion of the protocol-defined DLT assessment period of 28 days for the final dose-finding cohort
|
|
Overall response rate at week 6 - dose-extension part
Tijdsspanne: Week 6
|
Proportion of participants achieving a complete response (CR) or partial response (PR) at week 6 |
Week 6
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Intratumoral infiltration of GD2IL18CART
Tijdsspanne: Day 14
|
Presence and extent of GD2IL18CART-cell infiltration in on-treatment tumor biopsies |
Day 14
|
|
Expansion and persistence of GD2IL18CART
Tijdsspanne: From GD2IL18CART infusion through 12 months
|
Longitudinal assessment of GD2IL18CART-cell expansion, persistence and phenotype in peripheral blood |
From GD2IL18CART infusion through 12 months
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Medewerkers
Medewerkers
Onderzoekers
Onderzoekers
- Hoofdonderzoeker: Claudia Rossig, MD, University Children´s Hospital Münster
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata
- Neoplasmata per histologisch type
- Neoplasmata, glandulair en epitheel
- Neoplasmata, neuro-epitheliaal
- Neuro-ectodermale tumoren
- Neoplasmata, kiemcellen en embryonaal
- Neoplasmata, zenuwweefsel
- Sarcoom
- Neoplasmata, bindweefsel en zacht weefsel
- Neuro-ectodermale tumoren, primitief, perifeer
- Neuro-ectodermale tumoren, primitief
- Neoplasmata, botweefsel
- Neoplasmata, bindweefsel
- Neuroblastoom
- Sarcoom, Ewing
- Osteosarcoom
- Aminozuren, peptiden en eiwitten
- Eiwitten
- Antilichamen, monoklonaal, gehumaniseerd
- Antilichamen, monoklonaal
- Antilichamen
- Immunoglobulinen
- Immunoproteïnen
- Bloedeiwitten
- Serum -globulines
- Globulines
- Technologie, industrie en landbouw
- Receptoren, celoppervlak
- Membraaneiwitten
- Motorvoertuigen
- Transport
- Receptoren, immunologisch
- Receptoren, kunstmatig
- Receptoren, antigeen, T-cel
- Receptoren, antigeen
- Receptoren, cytoplasmatisch en nucleair
- Bevacizumab
- Auto
- Receptoren, chimeer antigeen
Andere studie-ID-nummers
Andere studie-ID-nummers
- UniMS26_026
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
De-identified individual participant data underlying the published results may be made available to qualified researchers upon reasonable request following publication, subject to applicable informed consent, ethical and data-protection requirements, and execution of an appropriate data-use agreement.
IPD-tijdsbestek voor delen
Beginning after publication of the primary study results and for a period of 5 years thereafter.
IPD-toegangscriteria voor delen
De-identified individual participant data underlying the published results may be made available to qualified researchers upon reasonable request. Requests will be evaluated based on scientific merit and compatibility with the participants' informed consent, applicable data-protection requirements, and institutional policies. Data will be shared following approval of the request and execution of an appropriate data-use agreement.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
- ICF
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .